 1995; 75426-439.J 
In the 19th century, the French concocted uin mariani, a drink mixture of coca leaves and wine, which reportedly reduced fatigue and hunger sensation during prolonged a~tivity.3,~ In the late 1800s, marathon runners frequently drank alcohol during races. Brandy, champagne, and another then-popular "stimulant," strychnine, were used by American athletes.3
In the 20th century, the use of stimulants in the 1952 Olympic Winter Games, followed by suspicion of anabolic steroid use by the soviet athletes in 1954, focused attention on the use of ergogenic aids.* The 1960s saw a dramatic increase in drug abuse, with amphetamines implicated in the deaths of several cyclists.' The apparent widespread use of anabolic steroids at the 1964 Olympics was severe enough to warrant drug testing at the 1968 Olympic Games.5 Improvements in detection using mass spectrometry and gas chromatography resulted in the disqualification of 19 athletes from the Pan-American Games in 1983, and in the surrender of a silver medal by Martti Vainio (1984 Olympic Games) and a gold medal by Canadian Ben Johnson (1988 Olympic game^) .^,^^^ Use of ergogenic aids by patients being treated by physical therapists might affect the patients' response to treatment. Side effects of some ergogenic aids can affect heart rate, blood pressure, or other physiologic measures. Individuals using injectable drugs are at risk for disease transmission from shared needle~.~.9 Adolescents and their parents often look to physical therapists providing sports physical therapy services at local schools for information on ergogenic aids. The physical therapist can be a valuable personal and community resource for facts about ergogenic aids.
"Ergogenic aids" is a broad category of topics (including physiologic, phannacologic, psychologic, and nutritional'), and the choice of substances used as ergogenic aids changes with improvements in technology and detection procedures. The list of techniques and substances used as ergogenic aids is too extensive for a complete discussion within this article The purposes of this article are to present several commonly abused agents and techniques, to examine their potential risks and benefits, and to discuss drug testing procedures.
Phannacologic Ergogenic Aids

Anabolic-Androgenic Steroids
Anabolic steroids are synthetic derivatives of the male hormone testosterone. These androgens are prescription drugs that have legitimate, therapeutic uses. They are prescribed for children and adolescents to treat delayed puberty, aplastic anemia, and hypogonadism.l0>" In the adult population, steroids are used successfully to treat certain types of anemias, hereditary angioedema, some gynecologic conditions, protein anabolism, and male hypogonadism. Additionally, they may have a role in the treatment of osteop0rosis.~~J3 Medical indications account for fewer than 3 million prescriptions of anabolic steroids annually in the United States.14 Illicit use, however, results in a much larger and untold number of annual usages.
Physical therapists may treat individuals who use anabolic steroids. Although some of these individuals may be taking steroids legally for medical purposes, it it more likely that patients will be t a h g these drugs illicitly. Knowledge of anabolic steroid side effects can help the physical therapist to recognize signs of abuse, and to educate the patient about the longterm deleterious effects of anabolic steroid use.
Epidemiology. The use of anabolic steroids for nonmedical purposes is not a new phenomenon. The first reported anabolic steroid use as an ergogenic aid occurred in 1954, and use became widespread in the athletic community by 1964.l3 Although anabolic steroid use by athletes has been in existence for more than 40 years, data from substance use surveys is relatively new. The first reports in the early 1970s revealed that 2.5% of Arizona high-school male athletes15 and 15% of Arizona State University athletes used anabolic steroids.16 Data have demonstrated that anabolic steroids are becoming increasingly popular among high-school athletes and nonathlete~.l5.~7-~0 In a 1988 nationwide survey, Buckley et all7 found that 6.6% of 3,403 male high-school seniors were using anabolic steroids, and 35.2% of these seniors were nonathletes. Of the steroid users, 38.3% reported first using anabolic steroids at age 15 years or younger, and another one third of the population had started by age 16 years. Steroid users reported using cycles of steroids lasting 6 to 12 weeks, and 40% of the steroid users had completed five or more cycles. "Stacking," or using more than one type of anabolic steroid concurrently, was practiced by 44% of the respondents, and 38.1% of the steroid users had used both oral and injectable methods of adrnini~tration.~~ Similar results were noted in an Arkansas study, where 11.1% of the 853 male 1 lth-grade students surveyed reported past or present use of anabolic ster o i d~.~~ Of the 1,881 Georgia highschool students surveyed in 1993, 6 .5% of the boys were taking anabolic steroids, with one fourth admitting to sharing needles to administer the drug.9 A recent sunrey of 3,047 highschool freshmen and seniors in Illinois revealed that 3% of the males and O.Y? of the females admitting use of anabolic steroids.20 Of those individuals using steroids, 64% were athletes, 26% reported using a stacking technique, and 21% listed a teacher/coach as the main source who got them interested in using steroids. Twentyone percent of steroid users started using steroids at age 15 years, 19?? started at age 14 years, and 7% started before the age of 10 years.
The National Collegiate Athletic Association (NCAA) has been collecting data on the use of anabolic steroids in collegiate athletes since 1985. Anabolic steroid use among male football players dropped from 9.7% of the players in 1989 to 5.0% of the players in 1993." Male basketball players showed an increase in use from 1.6% to 2.6941, and female basketball players showed an increase in use from 0.8% to 1.5%. For a list of the most commonly used anabolic steroids, see Table 1 .
Pharmacology and physiologic effects. All anabolic steroids are derivatives of the male sex hormone testosterone. The synthetic agents have a core steroid structure that gives them both anabolic (tissue building) and androgenic (masculinizing) e f f e~t s .~~~~ Physiologically, the anabolic and androgenic effects are inseparable. When the hormone binds with receptors in various tissues, the same type of receptors produce anabolic and androgenic effects. In some sites throughout the body, the hormone will bind and produce anabolic effects, whereas at other sites, it will bind and create androgenic effects. The most appropriate name for these compounds is "anabolic-androgenic steroids," but the term is frequently shortened to "anabolic steroids." Attempts to enhance the anabolic effects while diminishing the androgenic effects have brought about the creation of over 40 chemical 
Human Growth Hormone
Human growth hormone (GH) is identdied as a family of structurally related proteins synthesized by anterior pituitary somatotropes, of which the primary monomer is a 22,000-d, 191-amino acid polypeptide.jl Growth hormone is used for replacement therapy in children who are GH deficient. Additionally, GH is being studied for used in Turner's syndrome, children with delayed growth, and short children with intrauterine growth retardation or similar disorders.5'
Pharmacology and physiologic effects. The human pituitary contains between 5 to 10 mg of GH, with daily production of 0.4 to 1.0 mg in men and with slightly higher rates in adolescents and women.'j Serum levels vary throughout the day owing to its intermittent, pulsatile release, but average 0.5 to 3.0 pg/L and are affected by a number of factors. The half-life of GH ranges from 17 to 45 minutes, and proteolysis into a more bioavailable two-chain form takes place in the skeletal m~scle.~,5~153
The secretion of GH is controlled through a feedback loop involving GH-releasing hormone (GHRH) and somatotropin-release-inhibiting hormone (SRIH). Growth hormone release can be affected by multiple factors, including sleep, exercise, stress, hypoglycemia, alpha-adrenergic agonists, beta-adrenergic antagonists, GH levels, and dopaminergic agonists (Tab. 2).2.i2-55 Growth hormone increases in response to hypoglycemia and exercise, and the largest GH surge 
Clenbuterol
Clenbuterol is a beta2-adrenergic agonist that has proposed ergogenic properties resulting from central nervous system (CNS) stimulation. It is a sympathomimetic drug that has a peripheral excitatory action on smooth muscle, a cardiac excitatory function, and metabolic and endocrine actions.S2 These drugs are used primarily for their ability to produce relaxation in smooth muscle. The beta,-agonists are widely used as bronchodilators for the prevention and treatment of symptoms of exercise-induced asthma and for relaxation of the uterus in premature labor (Tab. 3). Administration. Clenbuterol hydrochloride is used as a bronchodilator in the management of asthma in usual doses of 20 pg two or three times daily by It is available as an oral preparation with a plasma half-life of 34 hours and a slightly longer tissue half-life. Changes in muscle growth can be obsewed within 2 days of treatment, with the maximum growth within 8 days65 Attenuation takes place after approximately 14 days, likely due to beta-receptor saturation and subsequent receptor down regulation. Rothwell et a169 demonstrated a 50% reduction in muscle beta-receptor density after 18 days of chronic clenbuterol treatment in rats. Intermittent administration of betaagonists has been shown to attenuate this effecL65 For this reason, athletes often "cycle" clenbuterol, taking it on and off in 2-day cycles. This cycle is generally continued for 8 to 10 weeks, followed by 10 to 12 weeks without the drug." Currently, no research supports this cycling schedule, although, as with many ergogenic aids, anecdotal reports exist. Anecdotal reports suggest that athletes often combine clenbuterol with other hormones such as anabolic steroids or GH to exponentially increase its effects, a practice that is supported by animal research.6" Ergogenic efficacy. Most studies of ergogenic efficacy have been performed on animals, although studies on humans with obesity are being initiated. Anabolic effects have been found, with 1@/o to 20% increases in muscle weight noted after 1 to 2 weeks of clenbuterol administration in rats.65,70 Rothwell and Stock67 found that a daily injection of clenbuterol (1 m g k g of body weight) produces a 12% weight gain and a 13% increase in the body proteinfat ratio in rats.
-
Administration of beta,-agonists appears to promote fiber-specific (fasttwitch glycolytic) muscular hypertrophy, with increases in the crosssectional area reported to be 1@/0 to 50% in a n i m a l~.~,~5 Maltin et aF4 found hypertrophy in the fast-twitch glycolytic fibers in animals treated with a daily dose of clenbuterol, and a combination of clenbuterol and GH resulted in hypertrophy in fast-twitch glycolytic, fast-twitch oxidative glycolytic, and slow oxidative fibers. Muscle RNA was increased consistent with the increase in muscle protein, and clenbuterol appeared to enhance protein anabolic effects via a depression of protein degradation rates, with little or no change in protein synthesis. Although other researchers have found similar anabolic changes, these effects were the result of increases in protein synthesis71 or increases in both synthesis and d e g r a d a t i~n .~~ Injection of clenbuterol (0.125 mg/kg of body weight) in rats resulted in increases in CAMP, blood lactate, muscle mass, and protein synthesis as well as decreases in muscle glycogen. 67 The increase in muscle mass was attributed to the protein synthesis increase, although the authors noted that the results may have been partly due to an altered rate of muscle protein degradati0t-1.~~ Other beta,-agonists (albuterol, salbutamol, cimaterol) have been studied to determine the potential ergogenic effects of these drugs. Morton et a173 studied the acute effects of a 200-pg dose of salbutamol inhalant on several physiologic variables and performance in high-level, nonasthrnatic athletes. The authors found no Merences in any measurements between treatment and placebo conditions. In contrast, Martineau et a174 studied the chronic effects of a 3-week, 16-mg/d administration of an oral form of sustainedrelease salbutarnol. The treatment group demonstrated increases in quadriceps femoris and hamstring muscle group strength compared with the control group. The single-dose and chronic-treatment effects, therefore, must be distinguished, and they may help explain the differences in study results. Length of treatment, dosage, route, and timing of clenbuterol administration can affect results.
Side effects. Side effects of clenbuterol use are slmilar to those of any beta,-agonist. Tremor, tachycardia, anxiety, palpitations, headache, nausea, anorexia, and insomnia are common complaints. Additionally, potentially serious side effects include cardiac muscle hypertrophy and dysrhythrnia, myocardial infarction, or stroke.66
Regulation. All oral beta-agonists, including clenbuterol, are banned by the IOC, the USOC, and the NCAA. Currently, oral clenbuterol is available only for veterinary use in the United States, whereas other oral betaagonists are widely used. Urine levels of 0.5 ng/mL are detectable by gas chromatography and mass spectrometry 2 to 4 days after the last dose.
Erythropoietin (EPO) is a glycoprotein produced by the kidney that functions to regulate red blood cell (RBC) production. This 36,000-d, 166-amino acid glycoprotein has a half-life of 6 to 9 hours. Approximately 90% of EPO is synthesized in the renal cortical cells, whereas the remainder is synthesized in extrarenal sites, primarily the live~-.~~,~~ Recombinant EPO (rEPO) was first available in Europe in 1987 and subsequently in the United States in 1989. Recombinant EPO is nearly identical to natural EPO both biochemically and immunologically, although some minor differences exist. Commercial production utilizes recombinant deoxyribonucleic acid (DNA) technology to manufacture rEPO from Chinese hamster ovary cells. Patients with anemia from various conditions, as well as patients anticipating blood loss from upcoming surgery, can benefit from the use of rEP0. 76, 77 Pharmacology and physiologic effects. Erythropoietin and rEPO are used specifically by endurance athletes Physical The :rapy / Volume 75, Number 5 / May 1995 to increase aerobic endurance, with effects similar to that of blood doping. Erythropoietin is a major factor in the stimulation, proliferation, and maturation of the bone marrow stem cell, which, in turn, increases the rate of RBC pr0duction.~5 Hypoxia, with a subsequent decrease in renal blood flow, or low levels of circulating hemoglobin stimulate the production and secretion of EPO by these sites. In normal bone marrow, stem cells differentiate into late burst erythroid colony forming units (BFU-E), which replicate and differentiate into early erythroid colony forming unit cells (CFU-E) and eventually into mature RBCs. This process normally takes approximately 7 days, with no new RBCs appearing for the first 2 days and with maximum RBC production reached after 5 or more days. Exogenous EPO is used in patients wlth end-stage renal disease and enhances RBC production by expanding the BFU-E and stimulating the CFU-E'~ (Figure) .
Administration. Administration of rEPO in patients with end-stage renal disease is recommended at a level of 150 U/kg three times per week with adjustmen& as necessary to achieve a response.7s The half-life of rEPO administered intravenously is approximately 5 to 11 hours, whereas the half-life is 25 hours when administered subcutaneously, depending on dosage. Absorption is slower with subcutaneous administration, with peak concentrations occurring 10 to 15 hours after administration.7679
Ergogenic efficacy. The proposed ergogenic benefits of EPO are derived from the early release of marrow reticulocytes (young RBCs), stimulation of megakarocytopoesis (platelet precursors), increased hemoglobin synthesis by KBC precursors, proliferation of BFU-E, and proliferation and dfierentiation of CFU-E cells. The resultant increase in RBCs will increase oxygen carrying capacity, thereby increasing oxygen availability to the tissues. Increased oxygen availability to the tissues al1c)ws for increased adenosine triphosphate (ATP) production and improved aerobic performance. Patients receiving 600 U/kg of body weight intravenously twice weekly for 21 days demonstrated a 41% greater RBC volume than did those receiving a p l a c e b~.~ Ekblom and BerglundB1 administered rEPO to 15 well-trained male subjects at a dosage of 50 U/kg subcutaneously three times per week for 6 weeks. Results demonstrated increased hematocrit of lO?h, exercise time to exhaustion by 17%, maximal oxygen consumption by 8%, and systolic blood pressure by 8%.
Side effects. Adverse effects of EPO or rEPO are due to the increase in RBC production and are dosedependent. Hypertension and hyperviscosity (hematocrit over 55%) of the blood are two potentially lifethreatening adverse effects. Athletes are particularly susceptible to the effects of hyperviscosity due to the unpredictable clearance of rEPO from the serum and the biological effects that last for the life of the RBC (up to 120 days). Effects may be exacerbated during prolonged endurance events when dehydration increases the hyperviscosity. Symptoms of hyperviscosity include headache, dizziness, vertigo, tinnitus, visual changes, angina, exercise-induced claudication, encephalopathy, and s e i~u r e s .~ The athlete may also experience a thromboembolic hypoxic event because of "sludging" of the blood. Several European cyclists mysteriously died (often at rest or while sleeping) between 1987 and 1990, which coincides with rEPO availability in Europe.82 It has been suggested that rEPO use in these athletes produced a vascular sludging, worsened by dehydration, eventually causing coronary artery 0cclusion.~3
Regulation. Blood doping of any kind, including use of EPO, is banned by the NCAA, the IOC, and the USOC.83 Unfortunately, detection of naturally occurring substances is difficult. Recombinant EPO is slightly different from EPO, and advances in technology may detect these ditferences. Assessment of the RBC age may be beneficial, as athletes abusing EPO should demonstrate a younger RBC population. Although the estimated yearly cost of legitimately obtained EPO of $5,000 to $6,000 may impede its use by some athletes, no definitive deterrents exist.83
Caffeine
Caffeine is the most widely consumed stimulant known today. Approximately 80% of the adult population in the United States consumes coffee or tea daily.H%offee is responsible for 90% of the caffeine consumption in the United States, totaling approximately 210 mg per person per day.85 Caffeine is also found in chocolate, soft drinks, weight-loss and cold preparations, and analgesics. Currently, the National Center for Drugs and Biologics lists caffeine as an ingredient in more than 1,000 over-the-counter pharmaceuticals.% Consequently, caffeine consumers include children as well as adults. Depending on preparation, a cup of coffee contains approximately 100 to 120 mg of caffeine, whereas a 12-02 soft drink contains 30 to 60 mg of caffeine. Analgesics and cold preparations contain approximately 30 to 65 mg of caffeine. 84 The physical therapist must be aware of the action and effects of caffeine because of its widespread use and its sympathetic and diuretic side effects.
Pharmacology and physiologic effects. Caffeine (1,3,7-trimethylxanthine) is one of three xanthine derivatives producing similar physiological responses.84-%,8' The other two derivatives, theobromine and theophylline, are found in cocoa and tea, respectively. Of the three xanthine derivatives, caffeine produces the most CNS activity and theobromine produces the least CNS activity.% After consumption, caffeine is completely absorbed from the gastrointestinal tract and reaches peak blood levels in approximately 30 to 60 minutes. Caffeine enters the brain quickly after absorption, thus producing the rapid alertness noted after c o n s u m p t i~n .~~ The highest concentrations following absorption are found in tissues with the highest water content, primarily the skeletal mu~cle.~5 The state of hydration, therefore, can affect caffeine distribution. The half-life of caffeine ranges from 2 to 12 hours in asymptomatic adults, with an average halflife of 4 to 6 hours. Children do not eliminate caffeine as readily as adults, and the effects may last up to 3 to 4 days in this p0pulation.~6
Caffeine is proposed to exert its effects by (1) antagonism of adenosine receptors:* (2) inhibition of enzyme activity such as phosphodiesterase,75 (3) altering the release or uptake of calcium from the sarcoplasmic r e t i c u l~m ,~5 >~~ (4) altering the calcium permeability of the sarcolemma, or (5) facilitating neuromuscular impulse transmi~sion.~~ Caffeine acts as a CNS stimulant, increasing arousal, reducing fatigue, decreasing motor reaction time, and changing normal electroencephalogram recordings. Excessive caffeine usage can produce irritability, restlessness, diarrhea, insomnia, and anxiety. Inhibition of phosphodiesterase results in elevated levels of CAMP, an important regulator of cellular functions. Maintenance of elevated CAMP levels results in increased neurotransmitter release and neuronal activation, regulation of hormone-induced glycogenolysis and lipolysis, and dose-specfic CNS s t i m u l a t i~n .~~~~ Central nervous system arousal is also facilitated directly by caffeine's inhibition of adenosine receptors in the brain. Adenosine acts as a CNS depressant, hypnotic, and anticonvulsant, and caffeine's blocking of adenosine receptors increases neurotransmitter release and lowers the threshold for neuronal activati0n.~5 In the athlete, the CNS stimulation may increase mental alertness and reduce fatigue.
In addition to decreasing the perception of fatigue, athletes use caffeine as an ergogenic aid because of its proposed ability to increase circulating levels of FFA and to "spare" glycogen by altering substrate utilization. Caffeine ingestion produces an increase in the plasma concentration of FFA and catecholamines and increases l i p o l y~i s .~~ Increased lipolysis has been attributed to either increased intracellular CAMP, which accelerates hydrolysis of stored triglycerides, or to direct xanthine inhibition of phosphodiesterase.8' The caffeine-facilitated increases in blood EFA levels are suggested to produce shifts in substrate utilization, increasing FFA oxidation and slowing glycolysis, thereby "sparing" glyc0gen.~99%
Ergogenic efficacy. Studies examining the glycogen sparing effect of caffeine have provided mixed results. Dserences in the quantity and timing of caffeine administration, variations in exercise protocols and subject nutritional status, and inconsistency in the caffeine "naivet~" of the subjects have likely produced this disparity. Tolerance to many of the effects of caffeine develops within a few days, and the results of caffeine ingestion on performance are highly dependent on an individual's normal quantity and schedule of caffeine c o n~u m p t i o n .~ Habitual caffeine consumption can attenuate heart rate and blood pressure, and catecholaminergic responses to acute caffeine administration can occur within a few days. 91 Fisher et aP2 found that habitual caffeine users Physical Th ~erapy / Volume 75, Number 5 /May 1995 developed a tolerance to the effects of caffeine, which was negated after a 4-day withdrawal period.
Costill et a189 found that elevated plasma FFA levels in seven cyclists who ingested 330 mg of caffeine resulted in a 40% decrease in the rate of muscle glycogen depletion, whereas several other researchers have failed to find an increase in FFA oxidation associated with increased blood FFA levels,' l-! ' 5 suggesting no change in substrate utilization.% Additionally, several researchers93~95~97,~ have found increased blood lactate levels following caffeine ingestion and exercise. Ravussin et a199 observed a higher rate of fat oxidation and decreased carbohydrate oxidation rates with increased plasma FFA levels only during the first 30 minutes of a 150-minute exercise session. Moreover, higher FFA levels did not alter substrate utilization after glucose feedings during exercise.
Flinn et allo0 studied the effects of a 10-mg/kg-' caffeine dose given 3 hours prior to an incremental cycle ergometer test in nine male caffeinenaive subjects. Subjects worked longer, performed more work, and exhibited higher FFA levels in the caffeine trial than during control or placebo trials. The authors concluded that caffeine was ergogenic when taken 3 to 4 hours prior to exercise in fasting subjects with diets normally low in caffeine. The effect of time of caffeine ingestion was evaluated in six trained, caffeine-naive men who consumed 10 mg/kg-' of caffeine immediately before a treadmill run to exhaustion.lol The athletes ran farther during the caffeine trial, and they had increased blood lactate and blood glucose responses at the end of exercise during the caffeine trial.
In contrast, Tarnopolsky et algl concluded that a 6-mg/kg-' caffeine dose administered 60 minutes prior to exercise in six habitual (200 mg/dP1) caffeine consumers had no potential ergogenic effect. Caffeine administration incrt~ased plasma FFA levels prior to and during exercise, but did not change oxygen consumption, heart rate, respiratory exchange ratio (RER), rate of perceived exertion (RPE), or neuromuscular function (maximal voluntary strength, peak twitch torque, and motor unit activation). Plasma levels of glucose, epinephrine, and norepinephrine were also unchanged. Although blood levels of FFA were increased in the caffeine trial, an associated increase in FFA oxidation was not observed.
A similar paradox was found in a study of five competitive cyclists who ingested a variety of potentially ergogenic substances in a crossover, single-blind protocol.% Caffeine given 60 minutes prior to exercise resulted in a reduction in muscle glycogen utilization when compared with the control trial. No difference, however, was noted in the RER between the caffeine and control trials, suggesting similar substrate utilization. These findings are similar to the results of a study of caffeine intake on performance in nine male marathoners, where an increase in plasma FFA was noted, with no change in RER." Titlow et a1102 also found no ergogenic benefit from ingesting 200 mg of caffeine prior to a treadmill test in five male subjects. The authors found no difference in performance or substrate utilization. Information on the caffeine habits of subjects in these studies was not provided, and tolerance to the effects of caffeine may explain the results. Additionally, it has been suggested that RER may not accurately reflect substrate utilization after caffeine ingesti0n.9~
Side effects. Side effects of caffeine may include trembling and tremors, insomnia, nervousness, irritability, and anxiety. Caffeine also has a diuretic effect, which may result in fluid imbalance and inconvenience for the athlete.
Regulation. Caffeine was considered a doping agent by the IOC until 1972, when caffeine was removed from the list of banned substances. This ruling was reconsidered, however, and in 1984 caffeine was again added to the list of doping agents. The illegal dosage is 12 mg/L of urine, and this dosage is equivalent to between 500 and 600 mg of caffeine in a 1-to 2-hour period.86 Caffeine is also banned by the NCAA at a urine level of 15 mg/L.
Drug Testing
Mandatory drug testing at international athletic events has been in existence at the Olympic Games since 1968. Comprehensive testing was not available until 1972, and testing for anabolic steroids was first initiated in 1976.2,103 The USOC and the NCAA have developed drug testing and drug education programs in attempts to ensure safe, fair competition. Mandatory drug testing programs were initiated in 1985 (USOC) and 1986 (NCAA) to eliminate the use of performance-enhancing and recreational drugs. Testing protocols, as well as analytical procedures for the most commonly used screening and confirmation tests, will be discussed.
Currently, the USOC drug testing program applies to the US Olympic Festival, the Pan-American Games, the World University Games, and the Olympic Trials and Games. The USOC athletes are subject to testing at any time throughout the year, including the off season. Athletes may be tested while out of competition for the presence of anabolic-androgenic steroids, diuretics, and masking agents.lo4 Short-notice testing requires only 48 hours' advance notice via phone, personal contact, or return-receipt correspondence. Division I-A and I-AA football players and Division I men's and women's track athletes can be tested throughout the academic year for anabolic steroids and related masking agents. All other athletes are tested at championship events and bowl games. Under NCAA and USOC protocols, athletes may be chosen for testing in a variety of ways. For example, first-, second-, and third-place finishers in addition to a random sample from the remaining field may be chosen for testing.lo4 Moreover, national governing bodies or NCAA schools may request or conduct their own drug testing programs. lo4 Although blood samples are currently under consideration for some drugs, such as EPO, urine is still the prePhysical Therapy / Volume 75, Number ferred specimen for three reasons: (1) Most misused drugs are present in higher concentrations in the urine than in blood, (2) larger specimens are obtained in an easier fashion, and (3) urine sampling is a noninvasive process.lo4 After selection for drug testing at an event, the athlete has 60 minutes in which to report, and a courier stays with the athlete during this time. After urine samples are collected under supervision at the drug testing station (at least 80 mL for KCAA athletes and at least 100 mL for USOC athletes), the urine is divided into two separate bottles. The urine in one bottle will undergo testing, and the other bottle is saved for use in the event of appeal.
Drug analysis involves two phases: screening and confirmation. Screening allows for rapid testing of many samples and is designed to eliminate all negative samples from further testing. If a screening test is positive, illicit drug use is presumed only, and the sample undergoes confirmation. Screening tests are sensitive, but confirmatory tests are specific for drug detection. A positive sample is confirmed by a second test performed on urine taken from the same test bottle. Testing procedures most commonly used in screening include thin-layer chromatography (TLC), irnmunoassay (IA), gas chromatography (GC), and high-performance liquid chromatography (HPLC). Gas chromatography/ mass spectrometry (GC/MS) is most often used for confirmation, as it provides the most specific and definitive identification possible.104
Thin-Layer Chmmatography
Thin-layer chromatography testing is based on the differences in the migration rate of various substances through a porous supporting medium.2 The degree of migration and the color are characteristic of certain drugs. Thinlayer chromatography can demonstrate the presence of a drug, but this procedure cannot speclfy the quantity of drug present.lo4 This technique is both time consuming and nonspecific, and provides only a positive or negative response. Thin-layer chromatography is capable of detecting only a limited number of substances 12 to 24 hours after ingestion, resulting in a high number of false-negative results.
lmmunoassay
Imrnunoassays use antigen-antibody interactions to detect illegal substances. Antibodies that bind selectively to certain drugs or drug metabolites are chosen, and the sensitivity and the specdicity of this test are only as good as the antibody chosen2 The binding is proportional to the amount of drug in the urine and can be detected through enzymes, radioisotopes, or fluorescent compounds. With this technique, very small amounts of drug can be detected in a very small amount of urine, although this test may not differentiate between specific drugs within a class of drugs. Immunoassay has yielded false-positive results with some decongestants and nonsteroidal anti-inflammatory drugs.2 Radioimmunoassay (RIA) and fluorescence polarization immunoassay (FPIA) are specific IA techniques currently being used. Radioimmunoassay can detect some 17a-methyl, 17a-ethyl, and 1Pnortestosterone steroids despite its low ~pecificity.~O5 Immunoassay is both more sensitive and more specdic than TLC.
Gas Chromatography
Gas chromatography uses a separation technique to divide the urine extracts into the component parts. An inert gas carries the urine through chromatographic columns, and the samples are separated by their boiling temperature and by their affinity for the column. Compounds are identdied by separation time, called retention time. The retention time is unique and reproducible for each drug in a given chromatographic c01urnn.~ High-performance liquid chromatography is similar to GC, except a liquid carries the sample through the chromotographic columns and the columns are not placed in a heated compartment. High-performance liquid chromatography is both sensitive and specdic, and it is simpler and faster than GC. Gas chromatography and HPLC are reliable methods for screening, and they allow for simultaneous determination of a wide variety of different compounds. High-performance liquid chromatography is used to screen for urinary caffeine levels and has been used to confirm the positive results obtained from other screening te~hniques.~ Some steroids can be analyzed with this technique, whereas HPLC and GC lack appropriate sensitivity to detect beta-adrenergic blo~kers.~O5J~~
Gas ChmmatographyIMass Spectrometry
The most precise procedure for detection of banned substances is a combination of GC and MS.1°3J05 Gas chromatography/mass spectrometry is a two-step process, where GC separates the sample into its constituent parts, while MS provides the exact molecular identdication of the compounds. Compounds are separated by GC and are then introduced, one at a time, into a mass spectrometer. As the sample constituents enter the MS, they are bombarded by electrons, which cause the compound to break up into molecular fragments. The fragmentation pattern is reproducible and characteristic, and is considered the "molecularfingerprint" of a specdic compound. Gas chromatography/mass spectrometry is considered to be the most definitive method for confirming the presence of a drug in the urine and is approximately 100 to 1,000 times more sensitive than TLC.* Selective ion monitoring has been used to improve the GC/MS results.1°5 This procedure is the most costly, averaging approximately $200 per sample to test.2
Summary
A variety of ergogenic aids are used by athletes attempting to gain an edge on a competitor. These aids fall into categories of nutritional, pharamcologic, physiologic, and psychologic. Some of these techniques have been shown to be efficacious when used in specific situations, whereas the benefit of others remains controversial. This controversy may be due to the ethical inability to test these substances in the same manner in which they are used. Moreover, blind testing is unable to be Physical Thera .py / Volume 75, Number 5 / May 1995 ~erformed in some situations (ana- 
